热门资讯> 正文
BioCryst任命Babar Ghias为首席财务官
2025-07-07 19:38
- BioCryst Pharmaceuticals (NASDAQ:BCRX) on Monday announced the appointment of Babar Ghias as chief financial officer and head of corporate development.
- Ghias joins BioCryst from AvenCell Therapeutics, where he served as CFO since 2022.
- Previously, Ghias was executive vice president of investments and portfolio management at Paragon Biosciences. He also served as chief financial and operating officer for several Paragon portfolio companies.
- Source: Press Release
More on BioCryst Pharmaceuticals
- BioCryst: Strong Opportunity For A Double With A Proven Therapy
- BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript
- BioCryst Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation
- BioCryst to sell European Orladeyo business for up to $264M
- BioCryst's Orladeyo up for FDA review in pediatric HAE patients
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
